Neoadjuvant use of oncolytic herpes virus G47? prevents local recurrence after insufficient resection in tongue cancer models

Mice with orthotopic tongue cancer received neoadjuvant G47? therapy. Neoadjuvant G47? and resection led to 10/10 survival even with insufficient resection margins. Overall design: Comparative gene expression profiling analysis of RNA-seq data for murine tongue tumors after intratumoral inoculation of G47?.